EUVIMEDSkopri EUVIMED
Crossref

Identification of Potent Leucine‐Rich Repeat Kinase 2 Inhibitors by Virtual Screening and Biological Evaluation

Hualiang Shen, Guoqi Yu, Tao Cai, Kai Hu, Tianbo Shang, Yanjuan Luo, Jiawei Zhu, Xiaoxue Bai, Yicheng Xiong, Meiyang Xi iD, Runpu Shen

Chemical Biology & Drug Design · 2025

DOI: 10.1111/cbdd.70082 ↗

At a glance

Journal article in Chemical Biology & Drug Design, 2025. Written by Hualiang Shen and 10 co-authors. Institution: Zhejiang Engineering Research Center of Fat-Soluble Vitamin, Shaoxing University, Shaoxing, China. Major MEDLINE topics: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Protein Kinase Inhibitors, Molecular Docking Simulation, Molecular Dynamics Simulation. Cited 3 times so far (Crossref); 26 references. Funded by: National Natural Science Foundation of China.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Parkinson's disease (PD) is the second most common neurodegenerative disease but has limited medications. Targeting leucine‐rich repeat kinase 2 (LRRK2) has been identified as a potential strategy for the treatment of PD. The development of LRRK2 inhibitors has attracted much interest, and various compounds have been reported with significant improvement in preclinical and clinical models. Currently, no LRRK2 inhibitor has been approved for PD intervention. Herein, we reported a virtual screening (VS) workflow combining molecular docking and molecular dynamics (MD) simulations to achieve eight compounds for further enzymatic assay. The results indicated a potent LRRK2 inhibitor 2 with IC 50 values of 2.396 and 5.996 μM against LRRK2 and LRRK2 G2019S, respectively, implying the reliability of this VS approach. Combined with predicted favorable drug‐like properties, this hit can be used as a starting point for further structural optimization, probably offering insight into targeting LRRK2 for PD treatment in the future.

Subjects

MeSH terms (MEDLINE)

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2Protein Kinase InhibitorsMolecular Docking SimulationMolecular Dynamics SimulationHumansParkinson DiseaseDrug Evaluation, PreclinicalBinding Sites

Author keywords

dockinginhibitory activityleucine‐rich repeat kinase 2 (LRRK2)molecular dynamics (MD) simulationsvirtual screening (VS)

Substances

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2Protein Kinase InhibitorsLRRK2 protein, human

Authors and institutions

  • Zhejiang Engineering Research Center of Fat-Soluble Vitamin, Shaoxing University, Shaoxing, China.
  • School of Chemistry and Chemical Engineering, Shaoxing University, Shaoxing, China.
  • School of Medicine, Shaoxing University, Shaoxing, China.
  • Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, China.

ORCID profiles: Meiyang Xi

Funding

  • National Natural Science Foundation of China

Cite

APA

Shen, H., Yu, G., Cai, T., Hu, K., Shang, T., Luo, Y., Zhu, J., Bai, X., Xiong, Y., Xi, M., & Shen, R. (2025). Identification of Potent Leucine‐Rich Repeat Kinase 2 Inhibitors by Virtual Screening and Biological Evaluation. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70082

Vancouver

Shen H, Yu G, Cai T, Hu K, Shang T, Luo Y, et al. Identification of Potent Leucine‐Rich Repeat Kinase 2 Inhibitors by Virtual Screening and Biological Evaluation. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70082

BibTeX
@article{Shen2025,
  author = {Shen, Hualiang and Yu, Guoqi and Cai, Tao and Hu, Kai and Shang, Tianbo and Luo, Yanjuan and Zhu, Jiawei and Bai, Xiaoxue and Xiong, Yicheng and Xi, Meiyang and Shen, Runpu},
  title = {Identification of Potent Leucine‐Rich Repeat Kinase 2 Inhibitors by Virtual Screening and Biological Evaluation},
  journal = {Chemical Biology & Drug Design},
  year = {2025},
  doi = {10.1111/cbdd.70082}
}
Start for free →